Addex Discontinue P-IIb/III Study of Dipraglurant for the Treatment of Dyskinesia Associated With Parkinson’s Disease
Shots:
- The company has decided to discontinue the P-IIb/III study evaluating dipraglurant in patients with dyskinesia associated with PD-LID
- The discontinuation is due to the slow recruitment of patients. Additionally, the company intends to concentrate on advancing its preclinical portfolio to the clinic and pursuing strategic collaborations for specific programs
- The results from the P-II study of ADX71149 in epilepsy patients are expected in Q4’22. Addex's ADX71149 is currently in a P-IIa PoC clinical trial for epilepsy. Indivior PLC has licensed Addex's GABABPAM program for drug candidate development with a focus on substance use disorder
Ref: Globenewswire | Image: Addex
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.